Roche Holding AG

Industry

  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Digital Health
    • Disease Management
  • Pharmaceuticals

Other Names/Subsidiaries

  • 454 Life Sciences
  • AAdheron Therapeutics
  • Amira Medical
  • Anadys Pharmaceuticals
  • AntlerA
  • ARIUS Research
  • Bina Technologies
  • BioImagene
  • BioVeris
  • Boehringer Mannheim
  • Carmot Therapeutics
  • Chugai Pharmaceutical
  • CompuChem
  • Disetronic
  • Dutalys
  • Enterprise Therapeutics
  • F. Hoffmann-La Roche
  • Foundation Medicine
  • ForSight VISION4
  • GenMark Diagnostics
  • Genentech
  • Genia Technologies
  • GlycArt Biotechnology
  • Good Therapeutics
  • Hoffmann-La Roche
  • Ignyta
  • Inception 5’ Inflazome
  • Igen International
  • Innovatis
  • InterMune
  • Jecure Therapeutics
  • Marcadia Biotech
  • Medingo
  • Memory Pharmaceuticals
  • Mirus Bio
  • mtm laboratories
  • National Health Laboratories
  • NimbleGen Systems
  • Piramed
  • Promedior
  • Poseida Therapeutics
  • PVT Probenverteiltechnik
  • Roche Diagnostics
  • Roche Innovation Center Copenhagen (formerly Santaris Pharma)
  • Seragon Pharmaceuticals
  • Spark Therapeutics
  • Stratos Genomics
  • Syntex
  • Tensha Therapeutics
  • Therapeutic Human Polyclonals
  • Trophos
  • Tusk Therapeutics
  • Ventana Medical Systems
See more in Biomedtracker

Latest on Roche Holding AG

Scrip

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

In another blow to Sarepta and its partner Roche, the European Medicines Agency’s human medicines committee, the CHMP, has decided against approving the beleaguered gene therapy, Elevidys (delandistro

Pink Sheet

EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

 
• By Eliza Slawther and Sarah Karlin-Smith

Elevidys (delandistrogene moxeparvovec), Sarepta / Roche ’s Duchenne muscular dystrophy gene therapy, failed to secure an approval recommendation from the European Medicines Agency’s human medicines

Scrip

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

Roche CEO Thomas Schinecker has added his voice to criticism of the middle men in the US biopharma sector, such as pharmacy benefit managers who negotiate discounts and rebates in exchange for reimbur

Scrip

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

Viking Therapeutics is continuing to advance dual GLP-1/GIP receptor agonist VK2735 on two tracks for obesity, with a pair of Phase III trials of the weekly injectable formulation under way, while a P